Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 377, Issue 4, 2008, Pages 1185-1190

  Takahashi Yanaga, Fumi ^a   Yoshihara, Tatsuya ^a   Jingushi, Kentaro ^a   Miwa, Yoshikazu ^a   Morimoto, Sachio ^a   Hirata, Masato ^b   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Celecoxib; Colon cancer cell; T cell factor (TCF); Wnt catenin signaling pathway

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; CELECOXIB; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR 7; WNT PROTEIN;

ARTICLE; CANCER CELL; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIMED DRUG RELEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LEUPEPTINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZOLES; SULFONAMIDES; T CELL TRANSCRIPTION FACTOR 1; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 56349123769     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.115     Document Type: Article

References (35)

1. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., and Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275 (1997) 1787-1790
2. Sparks A.B., Morin P.J., Vogelstein B., and Kinzler K.W. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58 (1998) 1130-1134
3. Bienz M., and Clevers H. Linking colorectal cancer to Wnt signaling. Cell 103 (2000) 311-320
4. Segditsas S., and Tomlinson I. Colorectal cancer and genetic alterations in Wnt pathway. Oncogene 25 (2006) 7531-7537
5. Reya T., and Clevers H. Wnt signalling in stem cells and cancer. Nature 434 (2005) 843-850
6. Taipale J., and Beachy P.A. The hedgehog and Wnt signalling pathways in cancer. Nature 411 (2001) 349-354
7. Kitagawa M., Hatakeyama S., Shirane M., Matsumoto M., Ishida N., Hattori K., Nakamichi I., Kikuchi A., Nakayama K., and Nakayama K. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J. 18 (1999) 2401-2410
8. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., and He X. Contorl of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108 (2002) 837-847
9. Thun M.J., Namboodiri M.M., and Heath C.W.Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325 (1991) 1593-1596
10. Chan T.A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 3 (2002) 166-174
11. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94 (2002) 252-266
12. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., and Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328 (1993) 1313-1316
13. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
14. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinbach G., and Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348 (2003) 883-890
15. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., and van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348 (2003) 891-899
16. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., and Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277 (2002) 27613-27621
17. Lee H.C., Park I.C., Park M.J., An S., Woo S.H., Jin H.O., Chung H.Y., Lee S.J., Gwak H.S., Hong Y.J., Yoo D.H., Rhee C.H., and Hong S.I. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J. Cell Biochem. 94 (2005) 597-610
18. Boon E.M., Keller J.J., Wormhoudt T.A., Giardiello F.M., Offerhaus G.J., van der Neut R., and Pals S.T. Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 90 (2004) 224-229
19. Dihlmann S., Siermann A., and von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 20 (2001) 645-653
20. Hawcroft G., D'Amico M., Albanese C., Markham A.F., Pestell R.G., and Hull M.A. Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23 (2002) 107-114
21. Dihlmann S., Klein S., and von Knebel Doeberitz M. Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol. Cancer Ther. 2 (2003) 509-516
22. Grösch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747
23. Schönthal A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 97 (2007) 1465-1468
24. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M., and Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 73 (2007) 1318-1329
25. Yamada M., Ohnishi J., Ohkawara B., Iemura S., Satoh K., Hyodo-Miura J., Kawachi K., Natsume T., and Shibuya H. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF). J. Biol. Chem. 281 (2006) 20749-20760
26. Maier T.J., Schilling K., Schmidt R., Geisslinger G., and Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469-1478
27. Grösch S., Tegeder I., Niederberger E., Bräutigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15 (2001) 2742-2744
28. Ilyas M., Tomlinson I.P., Rowan A., Pignatelli M., and Bodmer W.F. Β-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA 94 (1997) 10330-10334
29. Shureiqi I., Chen D., Lotan R., Yang P., Newman R.A., Fischer S.M., and Lippman S.M. 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 60 (2000) 6846-6850
30. Takahashi-Yanaga F., Taba Y., Miwa Y., Kubohara Y., Watanabe Y., Hirata M., Morimoto S., and Sasaguri T. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells. J. Biol. Chem. 278 (2003) 9663-9670
31. Mayer K., Wolff E., Clevers H., and Ballhausen W.G. The human high mobility group (HMG)-box transcription factor TCF-1:novel isoforms due to alternative splicing and usage of a new exon IXA. Biochim. Biophys. Acta 1263 (1995) 169-172
32. van de Wetering M., Castrop J., Korinek V., and Clevers H. Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. Mol. Cell. Biol. 16 (1996) 745-752
33. van Noort M., and Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev. Biol. 244 (2002) 1-8
34. Arce L., Yokoyama N.N., and Waterman M.L. Diversity of LEF/TCF action in development and disease. Oncogene 25 (2006) 7492-7504
35. Duval A., Rolland S., Tubacher E., Bui H., Thomas G., and Hamelin R. The human T-cell transcriptional factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res. 60 (2000) 3872-3879